For many patients diagnosed with advanced ovarian cancer, platinum-based chemotherapy is an important part of initial treatment. Platinum drugs, such as carboplatin and cisplatin, damage the DNA of cancer cells, making it harder for them to grow. These drugs are often used with other treatments as part of a care plan.
Sometimes, ovarian cancer continues to grow during platinum-based chemotherapy or returns relatively soon after treatment ends. Learning this can be overwhelming, but it does not mean the patient did anything wrong or that there are no other treatment options.
Platinum-Resistant VS Platinum-Refractory Cancer
Two terms are often used to describe how ovarian cancer responds to platinum treatment. Ovarian cancer that comes back within 6 months of the end of platinum-based chemotherapy is called platinum resistant. Cancer that grows while platinum-based treatment is still being given is called platinum refractory. These terms help the cancer care team describe how the cancer responded to treatment, which helps them decide what the next steps will be.
Although the 6-month time frame is commonly used, treatment decisions are not based on time alone. The care team may look at how the cancer responded earlier and how long that response lasted. They may also consider side effects, other treatments the person has received, current health, and personal preferences. Every person’s situation is different, so recommendations that are appropriate for one patient may not be appropriate for another.
When ovarian cancer is platinum resistant, next steps could include chemotherapy that does not contain platinum, targeted treatment, supportive care, or a clinical trial. Treatment goals can also vary. Depending on the situation, the goal may be to slow the cancer’s growth, relieve symptoms, preserve quality of life, or manage a combination of these goals.
Biomarkers and Clinical Trials
Testing the tumor for biomarkers, such as proteins, genes, or other changes found in cancer cells, helps the healthcare team better understand the cancer’s characteristics. Some results may also indicate whether a person qualifies for targeted treatment or a clinical trial.
Genetic testing can also show whether the cancer is linked to an inherited risk, which could be important for the patient and their family members. Patients can ask which genetic and tumor tests have already been done, what the results mean, and whether any additional testing might be helpful.
Clinical trials are another topic patients and caregivers may wish to discuss with the cancer care team. Clinical trials study new treatments, new combinations of existing treatments, and different ways of managing ovarian cancer and its symptoms. A clinical trial is not right for everyone, and whether someone can join depends on many factors. Asking about a trial does not mean a person has to take part; it simply provides a chance to learn whether a suitable study is available.
Questions to Ask Your Healthcare Team
- What does platinum-resistant ovarian cancer mean for me?
- Have genetic and biomarker tests been performed, and what do the results mean?
- What treatment options are available to me?
- Are there clinical trials that may be appropriate for me?
- What palliative and supportive care resources are available to me?
Side Effects and Palliative Care
Managing symptoms and treatment side effects, even when they are mild, is an important part of care. Ovarian cancer and its treatments can cause fatigue, pain, nausea, changes in appetite, nerve damage, or emotional distress.
Palliative care can be provided alongside cancer treatment to help manage symptoms, side effects, and emotional or practical concerns. Receiving palliative care does not mean that cancer treatment is ending. Services such as nutrition support, physical rehabilitation, counseling, social work, pain management, and patient navigation also help patients and caregivers maintain the best possible quality of life.
Caregivers can offer support by helping keep track of appointments, taking notes during medical visits, and encouraging the patient to share questions and concerns with the healthcare team. Caregivers should also pay attention to their own needs and seek support when caregiving becomes emotionally or physically difficult.
Platinum-resistant ovarian cancer presents challenges, but it does not define the whole person or the whole cancer experience. Treatment decisions are becoming more personalized as researchers learn more about ovarian cancer and its biomarkers. Clear communication with the healthcare team can help patients and caregivers understand the diagnosis, explore appropriate options, and make decisions that reflect the patient’s health, needs, and personal priorities.
Sources
- González-Martín A, Ledermann JA; ESMO Guidelines Committee. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer. ESMO Open. 2026;11:106032.
- Li H, Sheng J-J, Zheng S-A, et al. Platinum-resistant ovarian cancer: from mechanisms to treatment strategies. Genes Dis. 2025 August 11;13:101801.
- National Cancer Institute. Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ)–Patient version. Updated November 22, 2024. Accessed June 30, 2026. www.cancer.gov/types/ovarian/patient/ovarian-epithelial-treatment-pdq
- National Cancer Institute. Platinum resistant cancer. NCI Dictionary of Cancer Terms. Accessed June 30, 2026. www.cancer.gov/publications/dictionaries/cancer-terms/def/platinum-resistant-cancer
